



**Melaseq™
Solid Tissue Test**

*An advanced multi-gene test to assist
in the diagnosis of invasive melanoma*

*Available exclusively
at CLINICAL LABS*

Melanoma is the deadliest type of skin cancer and grows very quickly if left untreated. It can spread to deeper layers of the skin, then enter the lymphatic system or bloodstream. From there, it can spread to other parts of the body, such as the lungs, liver, brain or bones. **However, if caught early, 90% of melanomas can be cured with surgery.¹**

The Melaseq Solid Tissue Test analyses the makeup of melanoma, detecting multi-gene signs of the disease. This can assist doctors in the diagnosis of biologically challenging lesions, enabling more informed decisions in patient treatment and care.

How can the Melaseq Solid Tissue Test help me?

Assist in Improving Diagnosis and Accuracy

The Melaseq Solid Tissue Test provides doctors with an additional tool to help diagnose invasive melanoma more accurately. It can be used alongside visual-based diagnostic methods, including dermoscopy, biopsy and histopathology.

Enhanced Clarity for Complex Lesions

Using the latest technology, the Melaseq Solid Tissue Test analyses skin cells at a multi-gene level, with a 95% accuracy rate in clinical studies. It is particularly helpful for diagnosing atypical lesions, such as those that are biologically challenging to diagnose. Currently, when a diagnosis is uncertain, the doctor may ask for a second opinion. The Melaseq Solid Tissue Test can be used in addition to other tests to help provide a clearer, more confident diagnosis for complex invasive melanoma cases.

Does the Melaseq Solid Tissue Test require another biopsy?

The Melaseq Solid Tissue Test is performed on the same tissue sample that was taken during your initial biopsy. In most cases, no additional sample is required.



What will the Melaseq Solid Tissue Test tell me?

The Melaseq Solid Tissue Test will provide your doctor with a report that includes a Melaseq score ranging from 0 to 10.

- **Melaseq scores of 0 to 2.4** indicate a low probability of invasive melanoma and a lower risk of invasive skin melanoma.
- **Melaseq scores of 2.9 and above** indicate a high probability of invasive melanoma and the need for more intensive clinical management.

What happens after my result?

Potential patient care pathway based on Melaseq score:

- **For a high-probability score ≥ 2.9 :** Recommended follow-up care may include a wider local excision, consideration of sentinel lymph node biopsy, and adjuvant therapy, usually performed by a specialist skin cancer doctor.
- **For a low-probability score ≤ 2.4 :** Care options may include clinical observation/monitoring according to standard treatment guidelines, typically managed by primary care doctors or dermatologists.

Ordering the Melaseq Solid Tissue Test

Discuss the Melaseq Solid Tissue Test with your doctor to determine if it's suitable for you.

If you and your doctor decide to order the test, you will need to pay for it in full before analysis can be performed in our lab.



For secure online payment, please visit
pay.clinicallabs.com.au/melaseq
or scan the QR code.



If your doctor is registered in our pilot research program and has invited you to join, please choose the appropriate payment option on the website above.

For more information about Melaseq, including an easy-to-understand video, visit clinicallabs.com.au/melaseq.

1. Melanoma Institute Australia <https://www.melanoma.org.au/understanding-melanoma/melanoma-facts-and-statistics/>